BioCentury
ARTICLE | Company News

Celgene opts in for Triphase's proteasome inhibitor

November 18, 2016 10:49 PM UTC

Triphase Accelerator Corp. (San Diego, Calif.) said Celgene Corp. (NASDAQ:CELG) exercised its option to acquire Triphase's proteasome inhibitor marizomib (NPI-0052). Triphase will receive an undisclosed upfront payment, and is eligible for milestones. Celgene will be responsible for further development, and will fund Triphase's ongoing trials of the candidate.

Marizomib is in multiple clinical studies, including a Phase I/II trial to treat recurrent, grade IV malignant glioma; a Phase I trial to treat newly diagnosed glioma; and a Phase I trial to treat relapsed and refractory multiple myeloma (MM). ...